Virginia Kaklamani

1 month ago | onclive.com | Virginia Kaklamani

CommentaryPodcastMarch 10, 2025Author(s):Fact checked by:,Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm. Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care.

2 months ago | cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani

February 10, 2025By Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective.

2 months ago | cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani

February 10, 2025By Panelists discuss how locally advanced triple-negative breast cancer (LATNBC) is an aggressive breast cancer subtype characterized by absence of estrogen receptor, progesterone receptor, and HER2 protein expression. It presents with large tumors and/or extensive lymph node involvement without distant metastasis. Treatment typically involves neoadjuvant chemotherapy followed by surgery and radiation. Related Content Related Content

2 months ago | cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani

February 10, 2025By Panelists discuss how the approach to metastatic disease focuses on systemic therapy, as cancer has spread beyond its primary site. Treatment typically combines targeted therapy, immunotherapy, chemotherapy, and/or hormonal therapy based on cancer type and molecular profile. Goals shift toward extending survival, controlling symptoms, and maintaining quality of life rather than cure. Regular monitoring of treatment response and adverse effects guides ongoing care decisions.

2 months ago | cancernetwork.com | Rahul Gosain |Rohit Gosain |Virginia Kaklamani

February 10, 2025By Panelists discusses how triple-negative breast cancer (TNBC) treatment toxicities require careful monitoring and management. Common adverse effects include fatigue, nausea, hair loss, neuropathy from chemotherapy, and radiation-induced skin changes. Health care teams employ preventive strategies, dose modifications, and supportive care to minimize complications while maintaining treatment efficacy. Related Content Related Content